KCA
Search
- Page Path
- HOME > Search
Original Article
- Expression of c-kit and p53 in Non-small Cell Lung Cancers
- Jinyoung Yoo, Chi Hong Kim, So Hyang Song, Byoung Yong Shim, Youn Ju Jeong, Meyung Im Ahn, Sung Whan Kim, Deog Gon Cho, Min Seop Jo, Kyu Do Cho, Hong Joo Cho, Hoon-Kyo Kim
- Cancer Res Treat. 2004;36(3):167-172. Published online June 30, 2004
- DOI: https://doi.org/10.4143/crt.2004.36.3.167
-
Abstract
PDF
PubReader
ePub Purpose Increasing experimental evidence indicates that abnormal expression of c-kit may be implicated in the pathogenesis of a variety of solid tumors. It has been reported that over 70% of small cell lung cancer (SCLC) contain the c-kit receptor. In the present study, a c-kit analysis has been extended to non-small cell lung cancer (NSCLC). The expressions of p53, vascular endothelial growth factor (VEGF) and cd34, in addition to c-kit, were evaluated to investigate the correlations between these proteins and to determine their potential relationships with the clinicopathological data.
Materials and Methods Paraffin-embedded tumor sections, obtained from 147 patients with NSCLC, were immunohistochemically investigated using anti-c-kit, anti-p53, anti-VEGF and anti-cd34 antibodies.
Results c-kit was expressed in 40 (27%) of the tumors examined: 27% of the adenocarcinomas, 27% of the squamous cell carcinomas and 29% of the undifferentiated carcinomas. p53 and VEG F immunoreactivities were present in 107 (73%) and 110 (75%) carcinomas, respectively. Anti-cd34 was negative in all samples. No associations were established among these proteins. The c-kit, however, showed a strong correlation with the T factor: T1 (n=11), 0%; T2 (n=49), 16% and T3 (n=87), 37% (p=.006).
Conclusion It is suggested that in NSCLC c-kit is expressed relatively frequently and may become a therapeutic target for the patients with inoperable or recurrent c-kit positive tumors. The alterations in p53 probably constitute an early event, whereas the activated c-kit may contribute to tumor progression.
-
Citations
Citations to this article as recorded by
- Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis
Ying Su, Ru Chen, Zhongcheng Han, Rong Xu, Lili Ma, Reyina Wufuli, Hongbo Liu, Fang Wang, Lei Ma, Rui Chen, Jiang Liu
Pathobiology.2021; 88(4): 267. CrossRef - A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy
Ernest Osei, Julia Lumini, Dinindu Gunasekara, Beverley Osei, Akua Asare, Raymond Laflamme
Journal of Radiotherapy in Practice.2020; 19(4): 370. CrossRef - Design, synthesis and anti-cancer activity of pyrrole-imidazole polyamides through target-downregulation of c-kit gene expression
Mi Zhang, Jing Liang, Shi-Kun Jiang, Ling Xu, Yan-Ling Wu, Annoor Awadasseid, Xiao-Yin Zhao, Xu-Qiong Xiong, Hiroshi Sugiyama, Wen Zhang
European Journal of Medicinal Chemistry.2020; 207: 112704. CrossRef - Relative influence of c-Kit expression and epidermal growth factor receptor gene amplification on survival in patients with non-small cell lung cancer
HUI XIAO, JUAN WANG, YANAN LIU, LI LI
Oncology Letters.2014; 8(2): 582. CrossRef - Protein Kinase C-δ–Mediated Recycling of Active KIT in Colon Cancer
Misun Park, Won Kyu Kim, Meiying Song, Minhee Park, Hyunki Kim, Hye Jin Nam, Sung Hee Baek, Hoguen Kim
Clinical Cancer Research.2013; 19(18): 4961. CrossRef
- Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis
- 9,133 View
- 62 Download
- 5 Crossref
Case Report
- Solitary Fibrous Tumor Clinico: Pathological Analysis of 11 Cases
- Woo Sung Moon, Kwang Min Lee
- J Korean Cancer Assoc. 1999;31(4):847-854.
-
Abstract
PDF
- The clinico-pathological features of 11 solitary fibrous tumors (SFT) are described. The age of the patients ranged from 19 to 70 years (average, 43 years); 6 were male patients. Ten tumors were benign and arose in the pleura (three tumors), peritoneum (two), mediastinum (two), nasal cavity (one), thymus (one), and lacrimal gland (one). One tumor was histologically malignant and arose in the pleura. All of the tumors were grossly well circumscribed. The tumors measured from 0.8 cm to 50 cm in greatest diameter. Histologically, the tumors were composed of cytologically bland spindle cells arranged without obvious pattern; focally storiform, fascicular growth patterns and hemangioperi- cytoma-like vascular patterns were seen. Tumor cells were separated by thick bands of collagen demonstrating foci of keloid-like hyalinization. Increased mitotic activity (4 mitoses in 10 high-power fields) and high cellularity with mild cytologic atypia was noted in a pleural case, suspicious of malignant tumor, Immunohistochemically, all cases tested attained positivity for vimentin, CD34, and two cases showed focal myofibroblastic differentiation. Ultrastructural study of three cases showed mesenchymal cells with fibroblastic differentiation. Follow-up for 3 to 96 months (average, 39 months) showed no tumor recurrence or metastasis. SFT are easily overdiagnosed if strict criteria are not carefully applied, and strict diagnostic criteria are necessary to avoid confusion of SFT with more aggressive lesions.
- 2,529 View
- 15 Download
Original Articles
- Immunohistochemical Expression of CD34 and Vascular Endothelial Growth Factor in Hepatocellular Carcinoma
- Yeong Ok Kim, Bang Hur
- J Korean Cancer Assoc. 1999;31(4):802-810.
-
Abstract
PDF
- PURPOSE
Angiogenesis plays an important role in progression, invasion and metastasis of solid tumors. The Vascular Endothelial Growth Factor (VEGF) is thought to be a selective mitogen for endothelial cells. Hepatocellular carcinoma is a typical hypervascular tumor. However, the relationship between angiogenesis and angiogenic factor in hepatocellular carcinoma has not been evaluated. We investigated the relationship between microvessel density (MVD) and expression of VEGF in hepatocellular carcinoma.
MATERIALS AND METHODS
Immunohistochemlcal staining, using anti-CD34 and anti-VEGF antibodies, was applied in 32 cases of hepatocellular carcinoma. Also, relationship between these neovascular factors (MVD and VEGF expression) and clinicopathologic parameters such as tumor size, bistologic grade, alpha-fetoprotein level, hepatitis B virus surface antigen, presence of cirrhosis and survival was evaluated.
RESULTS
CD34 was reactive throughout the neoplastic tissue, albeit it was confined to a few periportal sinusoids and vessels in fibrous septa of adjacent cirrhotic liver. MVD was 59.6+22.7 and 44.3+21.5 in hepatocellular carcinoma and cirrhosis, respectively. VEGF was expressed in 9 cases (28.1%) of hepatocellular carcinoma, which was localized to the cytoplasm. MVD and VEGF expression was not significantly correlated (P>0.05). MVD was correlated with presence of cirrhosis and inversely conelated with alpha- fetoprotein level (p<0.05). MVD was not correlated with tumor size, presence of HBs antigen, histologic grade and survival (P>0.05). Expression of VEGF was not correlated with all clinicopathologic parameters (P>0.05).
CONCLUSION
These results indicate that MVD in hepatocellular carcinoma is not directly correlated with VEGF expression, and suggest that other angiogenic factor may be involved in neovascularization of hepatocellular carcinoma. However, CD34 expression is closely associated with neovascular process in cirrhosis and hepatocelluar carcinoma.
- 2,959 View
- 49 Download
- CD34+ Selected Peripheral Blood Stem Cell Transplantation
- Hoon Kook, Hyeoung Joon Kim, Jin Soo Hwang, Keun Mo Kim, Keun Mo Kim, Ik Joo Chung, Tai Ju Hwang
- J Korean Cancer Assoc. 1996;28(5):910-921.
-
Abstract
PDF
- The CD34 antigen is a 115 kDa glycoprotein that marks 1%-4% of human bone marrow cells, including virtually all committed progenitor cells and long-term reconstituting stem cells. The selection of CD34+ cells may be useful in several areas of clinical stem cell transplantation, including purging of tumor cells, T cell depletion, stem cell expansion and gene therapy. Using immunomagnetic beads method (Isolex-50TM), we report hereby the first two Korean experiences of CD34+ selected peripheral blood stem cell (PBSC) transplantations. As a mean of tumor cell purging, CD34+ cells were positively selected from mobilized PBPCs and infused to a 5-year-old girl with a relapsed stage IV neuroblastoma with resultant early short-term trilineage hematopoietic recovery. In the second patient with chronic myelogenous leukemia who showed poor graft function after having underwent an initial partially-matched bone marrow transplant, CD34+ selected allogeneic PBSC transplantation was attempted to reduce the likelihood of inducing graft-versus-host disease. Augmentation of marrow function was noted with infused PBSCs which were depleted of T cells to the degree of log3.65. As CD34+ selected PBSCs are capable of restoring hematopoietic recovery after high dose therapy, further development of selection technique to ensure high purging efficiency without significant loss of stem cells and further identification of best mobilizing and conditioning regimens are required in this new field of clinical transplantation.
- 2,677 View
- 19 Download
First
Prev
